Esperion rises, NanoString sinks after IPO
This article was originally published in Scrip
Executive Summary
Investors paid as much as $17.40 per share to own a piece of the hypercholesterolemia drug developer Esperion Therapeutics during the company's first day of trading on 26 June, but the stock closed at $14.50 – up 3.6% from the $14 initial public offering price.